LLY vs. VRTX

In the year-to-date period, LLY achieves a 30.09% return, which is significantly higher than VRTX's 10.90% return. Over the past 10 years, LLY has outperformed VRTX with an annualized return of 29.82%, while VRTX has yielded a comparatively lower 15.05% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current LLY Sharpe Ratio is 0.90, which is comparable to the VRTX Sharpe Ratio of 1.08. The chart below compares the historical Sharpe Ratios of LLY and VRTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

LLY's dividend yield for the trailing twelve months is around 0.69%, while VRTX has not paid dividends to shareholders.

The maximum LLY drawdown since its inception was -68.27%, smaller than the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for LLY and VRTX. For additional features, visit the drawdowns tool.

Eli Lilly and Company (LLY) has a higher volatility of 11.78% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 10.32%. This indicates that LLY's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Eli Lilly and Company and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.